Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Abandonment? Looks like it.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(95)
•••
Comment by G1945Von Apr 07, 2024 9:33am
163 Views
Post# 35975420

RE:RE:Abandonment? Looks like it.

RE:RE:Abandonment? Looks like it.
narmac wrote: Acchhhhh,,,the story is tooo good to let go,,,,,you watch and see,,,,I say JD is correct,,that some sleaze bag company will aquire or sell the platform and the next owner will market the illusion of unfathomable wealth from this technology. Lots of $$ is yet to made with a good promotion!!,,it may never go to trial in any form and still sell to newbie  investors with the same pie in the eye!

Just make sure we all know who the team was and follow the science platform to see where it goes and how the previous bufoons are connected to it and if they profit from it!


narmac, I'm sure the Bioasis platform will land in the hands of Lind Global Macro Fund, LP (“Lind”) & Biodexa the secured creditors, secured by liens over the assets of Bioasis with Lind holding first security.

And look at this: Biodexa Announces Positive Top-Line Phase 1 Clinical Trial Results for Diffuse Midline Glioma (Feb 23, 2024)


https://www.globenewswire.com/news-release/2024/02/23/2834442/0/en/Biodexa-Announces-Positive-Top-Line-Phase-I-Clinical-Trial-Results-for-Diffuse-Midline-Glioma-and-Provides-R-D-Update.html


G1945V
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities